Cite
MLA Citation
Martin Kaul et al.. “Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial.” Clinical and translational science, vol. 14, no. 5, 2021, pp. 1756–1768. http://access.bl.uk/ark:/81055/vdc_100144249995.0x000012